Research Alliance Corp IV

What changed: A Schedule 13G Joint Filing Agreement executed on July 20, 2026, documenting collective beneficial ownership of Class A Ordinary Shares, par value $0.0001 per share, of Research Alliance Corporation IV. The filing reports no alterations to the July 13, 2028 termination deadline, the $10.00 trust value per share, or the company’s searching status. It establishes a joint disclosure arrangement under Rule 13d-1(k)(1) among BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, and LAMPERT MARK N. Mark N. Lampert signs as authorized representative for each listed holder. The attached exhibit contains only the signature page and legal agreement language; it does not disclose share quantities, dates of acquisition, percentage ownership, or investment objectives. Why it matters: As a routine compliance exhibit, the filing consolidates reporting obligations across multiple affiliated vehicles and the named individual rather than modifying transaction mechanics. Because the primary Schedule 13G data table is absent, investors cannot determine whether the affiliated group’s stake approaches regulatory thresholds that might affect board oversight, merger negotiation dynamics, or sponsor governance before the July 2028 search window closes. The redemption calendar, trust preservation mechanics, and extension provisions remain untouched pending release of the complete ownership schedule.

What changed: A Schedule 13G beneficial ownership report filed to disclose that Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. are the designated reporting entities under Section 13(d) of the Exchange Act. The document names three reporting parties but contains zero share counts, purchase prices, date-of-acquisition fields, or narrative sections. It does not update redemption eligibility windows, trust account balances, extension voting timelines, target identification status, or sponsor compensation/conduct disclosures. Why it matters: As initially drafted, this 13G functions as a regulatory threshold notification rather than an operational update. Without embedded position data or a statement of purpose referencing RACD’s target search or business combination pathway, the filing carries no immediate impact on the July 13, 2028 dissolution deadline, investor cash-redemption calculations, or trust yield accruals. Materiality would only shift if a subsequent Amendment A schedules 0001193125-26-308898 discloses aggregate shares exceeding the five-percent line, specifies joint purchasing agreements that could form a de facto control group ahead of a merger vote, or ties the reporting entity to RACD’s management team or underwriters. Until then, the filing remains a static compliance record.

What changed: SEC Form 4 insider ownership report. On 2026-07-14, Matthew Hammond (director, Chief Executive Officer, 10% owner) acquired 275,000 shares at $10 via grant/award, resulting in post-transaction holdings of 275,000 shares. The filing does not modify the 2028-07-13 target deadline, the $10 per share trust value, redemption rights, or the company’s SEARCHING status. Why it matters: As a routine compliance exhibit, this Form 4 discloses executive equity allocation without triggering changes to investor redemption mechanics, trust account protections, or extension clauses. No assertions regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel appear in the filing. The reported figures and status are sourced directly from the issuer’s and reporter’s regulatory submission. While the grant reflects internal capital deployment, it carries no binding impact on the redemption calendar or business combination timeline.

What changed: Form 4 — insider ownership report filed with the SEC for Research Alliance Corp IV. According to the Form 4 submission by Research Alliance Holdings IV LLC, the reporting person acquired 275,000 shares at $10 via grant/award on 2026-07-14, concluding with 275,000 shares owned. The filing does not alter the SPAC’s SEARCHING status, trust account valuation, redemption price parameters, or the recorded 2028-07-13 termination deadline. Why it matters: As reported by Research Alliance Holdings IV LLC, the entity holds director status and a 10% ownership stake. The disclosed accumulation of 275,000 shares at the documented $10 price represents a completed founder equity allocation as the company approaches its 2028 liquidation window. Because the Form 4 contains no statements regarding target pipelines, merger negotiations, sponsorship conduct beyond standard equity grants, or marketing materials, the primary significance lies in the confirmed retention of founding capital alongside public shareholders approaching the redemption horizon. Trust mechanics and extension voting provisions remain unaffected by this insider transaction.

What changed: Form 8-K filing covering the consummation of Research Alliance Corporation IV's (RACD) initial public offering (IPO), including the underwriting agreement, trust agreement, registration rights agreement, private placement, charter amendments, director appointments, and a press release. On July 14, 2026, the company completed its IPO of 7,500,000 Class A ordinary shares at $10.00 per share, for gross proceeds of $75,000,000. Simultaneously, the Sponsor purchased 275,000 Private Placement Shares for $2,750,000. Total proceeds of $75,000,000 were deposited into a trust account. The company also appointed Alan Musso and John Maslowski to its board of directors and adopted an amended and restated memorandum and articles of association. Why it matters: This 8-K establishes the fundamental trust mechanics for this new SPAC. Per the filing, the trust holds $75,000,000 (including a $2,250,000 deferred underwriting discount) as of July 14, 2026. The trust value per share is $10.00 ($75,000,000 / 7,500,000 shares). The deadline to complete a business combination is 24 months from the closing of the IPO, or July 14, 2028. The document also details the lock-up agreements: Founder Shares are locked up for one year post-business combination (or earlier if certain price targets are met), and Private Placement Shares are locked up for 30 days post-business combination. The company is led by CEO Matthew Hammond and sponsored by RA Capital Management, focusing on healthcare targets.

What changed: Form 424B4 prospectus for the initial public offering of Research Alliance Corporation IV, a newly organized Cayman Islands exempted blank check company incorporated April 1, 2026. This filing establishes the baseline mechanics rather than modifying existing terms. According to the prospectus, the company operates under a strict 24-month completion deadline from the anticipated July 14, 2026 closing, with no specific target selected and no substantive discussions initiated. Why it matters: The 24-month expiration and mandatory extension redemptions establish the absolute liquidity horizon and capital preservation schedule for public investors. The founder share anti-dilution provision, structured to maintain a 15% converted ownership percentage excluding private placements and seller securities, interacts with the disclosed immediate net tangible book value dilution matrix—listing a $2.36 spread from the $10.00 offering price at 25% redemption down to negative $(0.65 ) at maximum redemption—which fundamentally alters post-combination equity valuations.

What changed: A routine SEC Form 3 compliance exhibit documenting initial insider beneficial ownership. Per the Form 3 filing submitted by Director John Michael Maslowski, zero non-derivative transactions or shareholdings were reported for Research Alliance Corp IV. This absence of activity leaves redemption thresholds, trust valuation mechanics, extension vote calendars, business combination pacing, and sponsor conduct metrics unchanged. Why it matters: For investors tracking SEARCHING-phase SPAC lifecycles, an inactive Form 3 confirms the director preserved static equity alignment through the 2026-07-10 reporting period. While the submission introduces no operational developments regarding target sourcing, bridge credit facilities, or underwriter conversion elections, it maintains the transparency baseline required to detect sudden capital reallocations. The unreported position against accession 0001608774-26-000004 suggests no shift in leadership conviction ahead of the dissolution timeline, providing no immediate impetus to adjust redemption probability models or extend the search window.

What changed: SEC Form 3 — initial statement of beneficial ownership reporting insider equity positions for Research Alliance Corp IV. According to the filing text submitted on 2026-07-10, reporting person Stusnick Henry William (identified in the submission as COO and CBO) disclosed zero non-derivative transactions and reported no existing non-derivative holdings. The document contains no references to modified redemption deadlines, trust-per-share recalibrations, extension votes, target acquisition milestones, or alterations to sponsor or executive conduct. Why it matters: For investors tracking redemption calendars, trust value mechanics, extension schedules, deal progression, or sponsor behavior, this routine compliance exhibit confirms that named leadership has not adjusted any equity positions and introduces no contractual or operational developments that would impact deSPAC execution. The filing makes no substantive claims regarding customer concentration, revenue projections, market sizing, technology roadmaps, partnership arrangements, ongoing litigation, or personnel changes beyond the standard COO/CBO title attribution. Because the SEC submission explicitly states 'No non-derivative transactions or holdings reported,' it functions as a procedural checkpoint that leaves the SEARCHING status, capital deployment timeline, and shareholder exit parameters unchanged. Investors monitoring these mechanics should anticipate that future material movements will originate from merger agreements, 8-K disclosures, proxy statements, or extension amendments rather than insider trade filings.

What changed: A Form 8-A for registration of certain classes of securities under Section 12(b) of the Exchange Act, registering Class A ordinary shares for listing on The Nasdaq Stock Market LLC. The Registrant registered the identical Class A ordinary shares (par value $0.0001) referenced in the S-1 prospectus initially filed June 8, 2026. The filing contains no amendments to redemption mechanics, trust account provisions, business combination timelines, or sponsor conduct. Chief Executive Officer Matthew D. Why it matters: This 8-A completes the Section 12(b) registration necessary for the Class A ordinary shares to trade on Nasdaq following the initial public offering tied to Registration Statement file number 333-296609. Because the document incorporates the full security description by reference from the June 8, 2026 prospectus rather than restating it, all underlying terms governing shareholder redemptions, trust distributions, and extension votes remain controlled by the original registration statement and any subsequently filed amendments.